Streptococcus

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Retrieved on: 
Thursday, November 10, 2022
GLOBE, AOM, S&P, Moraxella catarrhalis, Income, Vaccine, Accounting, Research, Pneumonia, Inactivated vaccine, Travel, Mouse, PCV13, Board, Streptococcus pneumoniae, G&A, Monkeypox, Share repurchase, Haemophilus influenzae, Antibody, CA, Development, Infection, Gastroenteritis, Time, Company, BWV, Disease, Water, Conference, Norovirus, VUK, Private law, Administration, Rotavirus, Cincinnati Children's Hospital Medical Center, Antigen, Congress, Pharmaceutical industry, Insurance, Haemophilus, Jude the Apostle, Streptococcus

On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.

Key Points: 
  • On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.
  • On November 8, 2022, the Company announced the appointment of Vuk Jeremi to its Board on November 4, 2022.
  • On November 9, 2022, the Board approved a share repurchase program to allow for the Company to repurchase up to 5 million shares, with discretion to management to make purchases subject to market conditions.
  • Cash Position: Cash was $29.1 million as of September 30, 2022, as compared to $1.9 million as of December 31, 2021.

New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation

Retrieved on: 
Thursday, November 10, 2022
Health, Consumer, Infectious Diseases, Children, Clinical Trials, Pharmaceutical, Biotechnology, PCV, PATH, Adult, GBS, Doctor of Philosophy, Severe acute respiratory syndrome coronavirus 2, Immunization, Pneumonia, Center, Technology, Streptococcus, Bill & Melinda Gates Foundation, Sepsis, Peterborough, Safety, Infection, Infant, HIA, Bill, CEO, Death, Volunteering, Meningitis, IVT, Trial of the century, Vaccine, Haemophilus

Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, Canada.

Key Points: 
  • Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, Canada.
  • This first-in-human study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • Were thrilled to now initiate the proof-of-concept evaluation in the clinic, says Dr. Subhash Kapre, Executive Chairman, Inventprise.
  • Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Company, Mumps, Polio, III, World, Influenza A virus subtype H1N1, World Health Organization, WHO, Foot-and-mouth disease virus, Hepatitis A, Vaccine, COVID-19, H5N1, CEO, National TB Elimination Program (India), Chickenpox, Seroconversion, HFMD, Oka, NASDAQ, Infection, R, Streptococcus, EV71, Program, Sinovac Biotech

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points: 
  • This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
  • Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
  • In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on: 
Friday, October 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, R, Chickenpox, Company, Influenza A virus subtype H1N1, Mumps, NASDAQ, Polio, H5N1, Vaccine, Pyaar Tune Kya Kiya (TV series), Foot-and-mouth disease virus, Booth, EV71, Streptococcus, Program, COVID-19, Infection, HFMD, Hepatitis A, WHO, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
  • At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
  • Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Retrieved on: 
Monday, October 24, 2022
SAN, Streptococcus pneumoniae, Conference, IND, Infection, Infant, Private Securities Litigation Reform Act, Investigational New Drug, Program, Mortality, Meningitis, 20B, Sinusitis, Chemistry, Bacteria, Subclinical infection, Streptococcus, Antigen, Immunoglobulin G, Pneumonia, Immunization, Company, 23F, GLOBE, Genetically modified bacteria, FDA, Sutro Biopharma, PD, Review, Vaccine, OPA, Security (finance), Ageing, U.S. Securities and Exchange Commission, Vaccination, PCV, Host, Immunodeficiency, Otitis media, Disease, Peterborough, SEC, Webcast, Periodontal disease, IPD, VAX, Adult, Safety, Fast Track, 10A, Death, Public health, Pharmaceutical industry, Generic drug, COVID-19

-- Vaxcyte to Advance Potential Best-in-Class VAX-24 Clinical Program in Adult and Pediatric Populations --

Key Points: 
  • These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard-of-care in adults.
  • We are thrilled with these positive topline results from our Phase 1/2 proof-of-concept study, which met all of our objectives.
  • The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care.
  • Topline safety, tolerability and immunogenicity data from the infant Phase 2 study primary 3-dose immunization series are expected by 2025.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.

Walgreens Flu Index Shows Flu Activity Trending 10 Times Higher Year Over Year

Retrieved on: 
Monday, October 24, 2022
Women, Infectious Diseases, Men, Family, Other Health, Health, Consumer, Pharmaceutical, General Health, Walgreens Boots Alliance, Infection, Streptococcus, COVID, National, Patient, Hospital, National Foundation for Infectious Diseases, Index, Nasdaq, Technology, Centers for Disease Control and Prevention, Health, Incidence, Season, Pharmacist, Map, Pharmacy, WBA, Meat, Vaccine, Walgreens

Through the time lapse feature of the Walgreens Flu Index, users can see how current flu activity compares to activity from last season.

Key Points: 
  • Through the time lapse feature of the Walgreens Flu Index, users can see how current flu activity compares to activity from last season.
  • On a weekly basis, Walgreens tracks the incremental change of antiviral medications used to treat influenza across thousands of Walgreens and Duane Reade locations nationwide to create the Walgreens Flu Index.
  • The Walgreens Flu Index is updated weekly each Tuesday and is available through an online, interactive map, linked here .
  • For example, red regions on the Walgreens Flu Index map indicates a much higher than a normal flu season, while green regions indicate a much lower than normal flu season.

Dr. B. Dental Solutions Simplifies the Care of Dentures and Oral Appliances with the Launch of Two New Products

Retrieved on: 
Wednesday, October 19, 2022
Dentures, Ultrasound, Disease, Stomatitis, Xerostomia, USB, Pneumonia, ADA, Infection, Smell, Escherichia coli, Liquid crystal, Fungus, Mouth, Staphylococcus, Red, Actinomyces, Candida albicans, Oral hygiene, Health, Face, Candida, Maintenance, American Dental Association, Dentistry, Streptococcus

Dallas, Texas--(Newsfile Corp. - October 19, 2022) - Dr. B Dental Solutions has announced the launch of two new products for people with dentures, implant retained or supported dentures, and removable dental appliances.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - October 19, 2022) - Dr. B Dental Solutions has announced the launch of two new products for people with dentures, implant retained or supported dentures, and removable dental appliances.
  • The two products - the Liquid Crystal disinfectant soak cleanser and UltraSonic cleaner, have been specifically designed to optimize health and simplify the care of dentures and dental appliances.
  • The Liquid Crystal Soak Cleanser from Dr. B's Dental Solutions is the only cleanser that fully disinfects disease-causing bacteria and fungi.
  • Individuals using dentures and dental appliances are prone to dry mouth, bad breath, sore spots as well as bacterial and fungal infections.

World Food, Beverages, Dietary Supplements and Animal Feed Probiotics (Lactobacillus, Bifidobacterium, Streptococcus, Bacillus) Market Analysis Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Retail, General Health, Health, Food, Beverage, Dietary supplement, Human–animal breastfeeding, Government, Review, Pharmacy, Animal, Probiotic, DSM, Animal feed, Research, Acquisition, Marketing, Industry, Bacillus, Supermarket, COVID-19, USD, Human, Renewable energy, Bifidobacterium, Lactobacillus, Drink, Food, Streptococcus

The report will provide an updated review of the global probiotics market, focusing on its genus, function, end-use, application, and sales channel.

Key Points: 
  • The report will provide an updated review of the global probiotics market, focusing on its genus, function, end-use, application, and sales channel.
  • Conclusive and detailed estimates and forecasts of the global probiotics market are provided, followed by a detailed analysis of regions, countries and manufacturers.
  • The report will include the COVID-19 impact analysis on the probiotics market at a global level.
  • The global probiotics market based on end use is segmented into probiotics for humans and probiotics for animals.

Global Conjugate Vaccine Market Report 2022: Increasing Rates of Pneumococcal Disease Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, Otitis, Adoption, Conjugation, Muscle, CDC, Sepsis, Disease, Streptococcus, Growth, Subclinical infection, Infection, CAGR, Whooping cough, WHO, Heart failure, Awareness, Ageing, Centers for Disease Control and Prevention, Paralysis, Vaccine

The increasing rates of pneumococcal disease is significantly contributing to market growth for conjugate vaccines.

Key Points: 
  • The increasing rates of pneumococcal disease is significantly contributing to market growth for conjugate vaccines.
  • The growing cases of blood infection, ear infection, sepsis across the globe, are in turn contributing to the growth of the global conjugate vaccine market.
  • The global conjugate vaccine market is segmented based on product type, disease, patient type and pathogen type.
  • Based on pathogen type the market is segmented into bacterial conjugate vaccine, viral conjugate vaccine and combination vaccine.